AAV-mediated lysophosphatidylcholine acyltransferase 1 (Lpcat1) Gene replacement therapy rescues retinal degeneration in rd11 mice

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 3, 2014, Pages 1724-1734

  Dai, Xufeng ^a   Han, Juanjuan ^a   Qi, Yan ^a   Zhang, Hua ^a   Xiang, Lue ^b   Lv, Jineng ^b   Li, Jie ^c   Deng, Wen Tao ^c   Chang, Bo ^d   Hauswirth, William W ^c   Pang, Ji Jing ^a,c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d JACKSON LABORATORY   (United States)

Author keywords

AAV; Gene therapy; Lpcat1; Mice; rd11

Indexed keywords

1 ACYLGLYCEROPHOSPHOCHOLINE ACYLTRANSFERASE; RHODOPSIN;

1 ACYLGLYCEROPHOSPHOCHOLINE ACYLTRANSFERASE GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTRORETINOGRAPHY; GENE; GENE MUTATION; GENE REPLACEMENT THERAPY; HISTOLOGY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MICROSCOPY; MOUSE; NONHUMAN; OPTIC NERVE; PHOTOPIC VISION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DEGENERATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; WESTERN BLOTTING;

AAV; GENE THERAPY; LPCAT1; MICE; RD11;

1-ACYLGLYCEROPHOSPHOCHOLINE O-ACYLTRANSFERASE; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DNA; DNA MUTATIONAL ANALYSIS; ELECTRORETINOGRAPHY; GENETIC THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MUTATION; RETINAL CONE PHOTORECEPTOR CELLS; RETINAL DEGENERATION; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84897860398     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13654     Document Type: Article

References (34)

1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795-1809.
2. Pang JJ, Lei L, Dai X, et al. AAV-mediated gene therapy in mouse models of recessive retinal degeneration. Curr Mol Med. 2012;12:316-330.
3. Friedman JS, Chang B, Krauth DS, et al. Loss of lysophosphatidylcholine acyltransferase 1 (LPCAT1) leads to photoreceptor degeneration in rd11 mice. Proc Natl Acad Sci U S A. 2010; 107:15523-15528.
4. Chen X, Hyatt BA, Mucenski ML, Mason RJ, Shannon JM. Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells. Proc Natl Acad Sci U S A. 2006;103:11724-11729.
5. Nakanishi H, Shindou H, Hishikawa D, et al. Cloning and characterization of mouse lung-type acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1). Expression in alveolar type II cells and possible involvement in surfactant production. J Biol Chem. 2006;281:20140-20147.
6. Pang JJ, Boye SE, Lei B, et al. Self-complementary AAVmediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Ther. 2010;17:815-826.
7. Pang JJ, Dai X, Boye SE, et al. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther. 2011;19:234-242.
8. Pang JJ, Deng WT, Dai X, et al. AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One. 2012;7:e35250.
9. Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol Ther. 2013;21:509-519.
10. Zhong L, Zhao W, Wu J, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther. 2007;15:1323-1330.
11. Petrs-Silva H, Dinculescu A, Li Q, et al. Highefficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther. 2009;17:463-471.
12. Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther. 2011;19:293-301.
13. Haire SE, Pang J, Boye SL, et al. Light-driven cone arrestin translocation in cones of postnatal guanylate cyclase-1 knockout mouse retina treated with AAV-GC1. Invest Ophthalmol Vis Sci. 2006;47:3745-3753.
14. Hauswirth WW, Lewin AS, Zolotukhin S, Muzyczka N. Production and purification of recombinant adeno-associated virus. Meth Enzymol. 2000;316:743-761.
15. Pang JJ, Boye SL, Kumar A, et al. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEβ mutation. Invest Ophthalmol Vis Sci. 2008;49: 4278-4283.
16. Pang JJ, Cheng M, Stevenson D, Trousdale MD, Dorey CK, Blanks JC. Adenoviral-mediated gene transfer to retinal explants during development and degeneration. Exp Eye Res. 2004;79:189-201.
17. Li W, Kong F, Li X, et al. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye. Mol Vis. 2009; 15:267-275.
18. Li X, Li W, Dai X, et al. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2011;52:7-15.
19. Zeng R, Zhang Y, Shi F, Kong F. A novel experimental mouse model of retinal detachment: complete functional and histologic recovery of the retina. Invest Ophthalmol Vis Sci. 2012;53:1685-1695.
20. Pang JJ, Chang B, Kumar A, et al. Gene therapy restores visiondependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther. 2006;13:565-572.
21. Kong F, Li W, Li X, et al. Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. Exp Eye Res. 2010;90:546-554.
22. Allocca M, Manfredi A, Iodice C, Di VU, Auricchio A. AAVmediated gene replacement either alone or in combination with physical and pharmacological agents results in partial and transient protection from photoreceptor degeneration associated with beta PDE deficiency. Invest Ophthalmol Vis Sci. 2011;52:5713-5719.
23. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358:2231-2239.
24. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358:2240-2248.
25. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130:9-24.
26. Dalkara D, Byrne LC, Lee T, Hoffmann NV, Schaffer DV, Flannery JG. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther. 2012;19:176-181.
27. Dalkara D, Byrne LC, Klimczak RR, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5:189ra76.
28. Weltzien HU. Cytolytic and membrane-perturbing properties of lysophosphatidylcholine. Biochim Biophys Acta. 1979;559: 259-287.
29. Wilson-Ashworth HA, Judd AM, Law RM, et al. Formation of transient non-protein calcium pores by lysophospholipids in S49 lymphoma cells. J Membr Biol. 2004;200:25-33.
30. Tummala P, Mali RS, Guzman E, Zhang X, Mitton KP. Temporal ChIP-on-Chip of RNA-Polymerase-II to detect novel gene activation events during photoreceptor maturation. Mol Vis. 2010;16:252-271.
31. Mansilla F, da Costa KA, Wang S, et al. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer. J Mol Med (Berl). 2009;87:85-97.
32. Zhou X, Lawrence TJ, He Z, Pound CR, Mao J, Bigler SA. The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer. Exp Mol Pathol. 2012;92:105-110.
33. Morita Y, Sakaguchi T, Ikegami K, et al. Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. J Hepatol. 2013;59:292-299.
34. Bridges JP, Ikegami M, Brilli LL, Chen X, Mason RJ, Shannon JM. LPCAT1 regulates surfactant phospholipid synthesis and is required for transitioning to air breathing in mice. J Clin Invest. 2010;120:1736-1748.